GILD

128.84

0.32% -0.42

Handel nachbörslich: 128.00 -0.84 -0.65%

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$129.26

Offen:

$128.9

24-Stunden-Volumen:

4.92M

Relative Volume:

0.75

Marktkapitalisierung:

$159.92B

Einnahmen:

$29.45B

Nettoeinkommen (Verlust:

$8.51B

KGV:

19.00

EPS:

6.7823

Netto-Cashflow:

$9.46B

1W Leistung:

-3.05%

1M Leistung:

-4.03%

6M Leistung:

+8.73%

1J Leistung:

+23.63%

1-Tages-Spanne:

$128.00

$129.96

1-Wochen-Bereich:

$127.64

$134.68

52-Wochen-Spanne:

$95.30

$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Firmenname

Gilead Sciences Inc

Sektor

Healthcare (1108)

Branche

Drug Manufacturers - General (20)

Telefon

(650) 574-3000

Adresse

333 LAKESIDE DR, FOSTER CITY, CA

Mitarbeiter

17,000

Twitter

@GileadSciences

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, MRK

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GILD Gilead Sciences Inc	128.84	160.44B	29.45B	8.51B	9.46B	6.7823
LLY Lilly Eli Co	851.21	780.79B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	227.35	548.34B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	203.89	349.67B	61.16B	4.19B	17.82B	2.3614
AZN Astrazeneca Plc	185.20	289.51B	58.80B	10.24B	8.98B	3.2788
MRK Merck Co Inc	110.95	271.76B	64.93B	18.26B	12.36B	7.2751

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-10	Eingeleitet	Jefferies	Buy
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-11	Bestätigt	Needham	Buy
2026-01-07	Fortgesetzt	UBS	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-08-19	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-08-08	Hochstufung	Truist	Hold → Buy
2025-07-25	Hochstufung	Needham	Hold → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-03-04	Bestätigt	Oppenheimer	Outperform
2025-02-18	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-13	Hochstufung	DZ Bank	Hold → Buy
2025-01-10	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Fortgesetzt	BofA Securities	Buy
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Buy
2024-11-08	Herabstufung	Maxim Group	Buy → Hold
2024-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-17	Eingeleitet	Bernstein	Outperform
2024-10-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-07-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2024-05-01	Bestätigt	Maxim Group	Buy
2024-04-24	Hochstufung	HSBC Securities	Reduce → Hold
2024-02-22	Herabstufung	Truist	Buy → Hold
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-09-08	Hochstufung	BofA Securities	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Reduce
2023-07-24	Bestätigt	Barclays	Equal Weight
2023-05-16	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Fortgesetzt	Piper Sandler	Overweight
2023-01-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Fortgesetzt	BofA Securities	Neutral
2022-12-09	Herabstufung	DZ Bank	Buy → Hold
2022-10-31	Hochstufung	Barclays	Underweight → Equal Weight
2022-10-28	Bestätigt	BMO Capital Markets	Market Perform
2022-10-28	Bestätigt	Cowen	Outperform
2022-10-28	Bestätigt	JP Morgan	Overweight
2022-10-28	Bestätigt	Jefferies	Buy
2022-10-28	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-28	Bestätigt	RBC Capital Mkts	Outperform
2022-10-28	Hochstufung	Truist	Hold → Buy
2022-10-28	Bestätigt	Wells Fargo	Equal Weight
2022-10-04	Hochstufung	JP Morgan	Neutral → Overweight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-02-28	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Bestätigt	BMO Capital Markets	Outperform
2022-02-02	Bestätigt	BofA Securities	Neutral
2022-02-02	Bestätigt	RBC Capital Mkts	Outperform
2022-02-02	Bestätigt	Truist	Hold
2022-02-02	Bestätigt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Argus	Hold → Buy
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Fortgesetzt	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Fortgesetzt	Piper Sandler	Neutral
2021-10-20	Fortgesetzt	Cowen	Outperform
2021-07-30	Bestätigt	BMO Capital Markets	Market Perform
2021-07-30	Bestätigt	RBC Capital Mkts	Outperform
2021-04-01	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-03-30	Hochstufung	Redburn	Neutral → Buy
2021-01-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-11-03	Fortgesetzt	Morgan Stanley	Equal-Weight
2020-10-28	Eingeleitet	UBS	Neutral
2020-09-30	Fortgesetzt	Jefferies	Buy
2020-09-15	Hochstufung	Maxim Group	Hold → Buy
2020-07-31	Bestätigt	Credit Suisse	Neutral
2020-07-31	Bestätigt	Morgan Stanley	Equal-Weight
2020-07-31	Bestätigt	Piper Sandler	Overweight
2020-07-31	Bestätigt	RBC Capital Mkts	Outperform
2020-07-31	Bestätigt	SunTrust	Hold
2020-07-31	Bestätigt	Wells Fargo	Equal Weight
2020-07-20	Hochstufung	Credit Suisse	Underperform → Neutral
2020-06-03	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Hochstufung	SunTrust	Sell → Hold
2020-05-01	Herabstufung	JP Morgan	Overweight → Neutral
2020-05-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-01	Herabstufung	SunTrust	Hold → Sell
2020-04-27	Herabstufung	UBS	Buy → Neutral
2020-04-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Herabstufung	CFRA	Hold → Sell

Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

06:41 AM

Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD) - Stock Titan

06:41 AM

06:23 AM

Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock - Investing.com

06:23 AM

05:53 AM

Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan

05:53 AM

03:13 AM

Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st

03:13 AM

02:16 AM

Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com

02:16 AM

12:10 PM

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir - BioSpace

12:10 PM

12:02 PM

GILD: Gilead's New HIV Treatment Gains FDA Acceptance - GuruFocus

12:02 PM

11:31 AM

Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com Nigeria

11:31 AM

10:06 AM

Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat

10:06 AM

09:32 AM

Gilead Sciences stock edges higher as FDA grants priority review for HIV treatment - Traders Union

09:32 AM

09:05 AM

FDA accepts Gilead’s HIV treatment combination for review - Investing.com

09:05 AM

05:24 AM

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

05:24 AM

Apr 28, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 28, 2026

Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares - Stock Titan

Apr 28, 2026

Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

Apr 28, 2026

Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - Blockonomi

Apr 28, 2026

Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - CoinCentral

Apr 28, 2026

Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com

Apr 28, 2026

Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. - Barron's

Apr 28, 2026

Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com

Apr 28, 2026

Gilead Completes $7.8 Billion Acquisition of Arcellx - Contract Pharma

Apr 28, 2026

Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx - marketscreener.com

Apr 28, 2026

Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus

Apr 28, 2026

Recent Arcellx deal leaves Gilead Sciences stock consolidating amid persistent oversold signals - Traders Union

Apr 28, 2026

Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz

Apr 28, 2026

Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx to Accelerate Launch of Anito-cel CAR T Therapy for Multiple Myeloma 1 - Minichart

Apr 28, 2026

Gilead Sciences Completes Acquisition of Arcellx and Anito-cel - TipRanks

Apr 28, 2026

Gilead fully acquires Arcellx (NASDAQ: ACLX) as tender offer and merger close - Stock Titan

Apr 28, 2026

Gilead completes $7.8 billion acquisition of Arcellx - Investing.com

Apr 28, 2026

Gilead Sciences reports new GTPase KRAS G12D inhibitors and degraders - BioWorld News

Apr 28, 2026

Gilead completes $7.8 billion acquisition of Arcellx By Investing.com - Investing.com Canada

Apr 28, 2026

Gilead (NASDAQ: GILD) closes Arcellx deal, gains full control of anito-cel - Stock Titan

Apr 28, 2026

Gilead Sciences (ACLX) to close merger; 77.2% tendered, $115 cash plus CVR - Stock Titan

Apr 28, 2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire

Apr 28, 2026

Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Apr 28, 2026

M&T Bank Corp Sells 147,548 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 28, 2026

Apr 27, 2026

Stanford symposium appearance sees Gilead Sciences stock drop 2.03% - Traders Union

Apr 27, 2026

Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch

Apr 27, 2026

Gilead Sciences (GILD) Builds Defensive Moat With HIV Franchise Ahead of May 7 Earnings - AlphaStreet

Apr 27, 2026

Pictet Asset Management Holding SA Sells 326,886 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 27, 2026

State of Michigan Retirement System Sells 10,800 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 27, 2026

Sanctuary Advisors LLC Has $27.19 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Apr 27, 2026

Gilead Sciences Obtains Regulatory Approval for Arcellx Acquisition - HarianBasis.co

Apr 27, 2026

Gilead Sciences (GILD) Set to Acquire Arcellx - Insider Monkey

Apr 27, 2026

Apr 26, 2026

A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress - Yahoo Finance

Apr 26, 2026

Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN

Apr 26, 2026